The U.S. Food and Drug Administration (FDA) granted initial approval to Dapagliflozin And Metformin Hydrochloride, a generic combination drug developed by ALKEM LABS LTD., on April 6, 2026. This approval marks the availability of a new generic option for this widely used medication.
Background
Dapagliflozin And Metformin Hydrochloride is a generic combination drug containing dapagliflozin and metformin hydrochloride. It is a generic version of the brand-name product Xigduo XR. The active ingredient dapagliflozin is also available as the single-ingredient product Farxiga. Other related drugs in the market include canagliflozin and empagliflozin.
What this means
The initial FDA approval of a generic combination drug like Dapagliflozin And Metformin Hydrochloride typically expands treatment options for patients. Generic medications are required to demonstrate bioequivalence to their brand-name counterparts, ensuring they provide the same clinical benefit at a potentially lower cost. This approval by the FDA for ALKEM LABS LTD. is expected to increase patient access to this medication.
Source
The information regarding this initial FDA approval was sourced from the U.S. Food and Drug Administration (FDA) website, specifically the Center for Drug Evaluation and Research (CDER) database, on April 6, 2026. The approval details are available at accessdata.fda.gov.